Biocryst Pharmaceuticals (BCRX) Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea
8/16/2010 8:00:29 AM
BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA (Korean Food & Drug Administration) for intravenous (i.v.) peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu® in South Korea.
comments powered by